Dr Dory Abelman speaks to ecancer about advancements in minimal residual disease detection in myeloma.

Traditional methods for detecting minimal residual disease in myeloma include counting cancer cells and using multi-parameter flow cytometry.

New techniques like adaptive clonal sequencing and cell-free DNA analysis improve detection by focusing on mutations.

Challenges include accessing tumour cells and differentiating mutations.

A clinical trial is validating these technologies, aiming for better patient outcomes.

Dr Ableman concludes by saying that the future lies in less invasive blood tests and enhanced DNA analysis.